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Free radicalsTetrahydrobiopterin (BH4) is a required cofactor for the synthesis of NO by endothelial nitric oxide synthase
(eNOS), and endothelial BH4 bioavailability is a critical factor in regulating the balance between NO and
superoxide production (eNOS coupling). Biosynthesis of BH4 is determined by the activity of GTP-cyclohydrolase
I (GTPCH). However, BH4 levelsmay also be inﬂuenced by oxidation, forming 7,8-dihydrobiopterin (BH2),which
promotes eNOS uncoupling. Conversely, dihydrofolate reductase (DHFR) can regenerate BH4 from BH2, but
whether DHFR is functionally important in maintaining eNOS coupling remains unclear. To investigate the
mechanism bywhich DHFRmight regulate eNOS coupling in vivo, we treated wild-type, BH4-deﬁcient (hph-1),
and GTPCH-overexpressing (GCH-Tg) mice with methotrexate (MTX), to inhibit BH4 recycling by DHFR. MTX
treatment resulted in a striking elevation in BH2 and a decreased BH4:BH2 ratio in the aortas of wild-type mice.
These effectsweremagniﬁed inhph-1 but diminished inGCH-Tgmice. Attenuated eNOS activitywas observed in
MTX-treatedhph-1 but notwild-type orGCH-Tgmouse lung, suggesting that inhibition ofDHFR inBH4-deﬁcient
states leads to eNOS uncoupling. Taken together, these data reveal a key role for DHFR in regulating the BH4 vs
BH2 ratio and eNOS coupling under conditions of low total biopterin availability in vivo.rabtree).
NC-ND license.© 2011 Elsevier Inc.Open access under CC BY-NC-ND license.In vascular disease states such as atherosclerosis and diabetes,
endothelial nitric oxide (NO) bioactivity is diminished and oxidative
stress is increased, resulting in endothelial dysfunction. It has become
apparent that enzymatic “coupling” of endothelial NO synthase (eNOS)
by thecofactor tetrahydrobiopterin (BH4)plays a key role inmaintaining
endothelial function. Indeed, the balance between NO and superoxide
production by eNOS seems to be determined by the availability of BH4,
whereas BH4 oxidation forms 7,8-dihydrobiopterin (BH2), which is
inactive for NOS cofactor function and may compete with BH4 for NOS
binding and increase eNOS uncoupling [1]. Intracellular biopterin levels
are regulated principally by the activity of the de novo biosynthetic
pathway (Fig. 1). Guanosine triphosphate cyclohydrolase I (GTPCH;
EC 3.5.4.16) catalyzes the formation of dihydroneopterin triphos-
phate from GTP, and BH4 is generated by two further steps through
6-pyruvoyltetrahydropterin synthase and sepiapterin reductase.
GTPCH seems to be the rate-limiting enzyme in BH4 biosynthesis,
and overexpression of GTPCH is sufﬁcient to augment BH4 levels in
cultured endothelial cells [2]. Electron paramagnetic resonance
spectroscopy studies have shown that BH4 both stabilizes and donates
electrons to the ferrous–dioxygen complex in the oxygenase domain,
as the initiating step of L-arginine oxidation [3–5]. In this reaction
BH4 forms the protonated trihydrobiopterin cation radical, which is
subsequently reduced by electron transfer from NOS ﬂavins. WhenBH4 availability is limiting, electron transfer from NOS ﬂavins becomes
uncoupled from L-arginine oxidation, eNOS generates superoxide rather
than NO, and BH4 becomes oxidized to catalytically incompetent BH2,
resulting in a cascade of BH4 loss [1]. Recent studies reveal that BH4 and
BH2 bind eNOSwith similar afﬁnity and that BH2 can efﬁciently replace
eNOS-bound BH4, resulting in eNOS uncoupling [6]. Indeed, we have
previously shown that the relative abundance of eNOS vs BH4, together
with the intracellular BH4:BH2 ratio, rather than absolute concentra-
tions of BH4, is the key determinant of eNOS uncoupling [7]. Thus,
mechanisms that regulate the BH4:BH2 ratio, independent of overall
biopterin levels, may play a role in controlling eNOS coupling that is
equally as important as the well-established role of GTPCH in de novo
BH4 biosynthesis.
In addition to key roles in folatemetabolism, dihydrofolate reductase
(DHFR; EC 1.5.1.3) can reduce BH2, regenerating BH4 [8,9]. Thus, it is
likely that net BH4 cellular bioavailability reﬂects the balance between
denovoBH4synthesis, loss of BH4byoxidation toBH2, and regeneration
of BH4 by DHFR. In human liver extracts, DHFR has been shown to
reduce BH2 to BH4aspart of the salvage pathway for biopterin synthesis
[10]. Recent studies have investigated the recycling function of DHFR in
cultured endothelial cells. Exposure to angiotensin II down-regulated
DHFR expression, decreasedBH4 levels, and increased eNOSuncoupling,
which was restored by overexpression of DHFR [2]. Pharmacological
inhibition of DHFR activity by methotrexate, or genetic knockdown of
DHFR by RNA interference, diminished intracellular BH4 and increased
BH2 levels resulting in enzymatic uncoupling of eNOS in endothelial
cells. In cells expressing eNOSwith lowbiopterin levels, DHFR inhibition
Fig. 1. Schematic representation of the BH4 recycling pathway and eNOS coupling. BH4
is synthesized de novo from GTP via a series of reactions involving GTPCH, 6-
pyruvoyltetrahydropterin synthase, and sepiapterin reductase (−−−). DHFR can
regenerate BH4 from BH2 as part of the recycling pathway. Both BH4 and BH2 bind
eNOS with equal afﬁnity, however, BH4-bound eNOS produces NO, whereas BH2-
bound eNOS promotes uncoupling and eNOS-derived superoxide rather than NO.
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eNOS uncoupling [11,12].
Despite these insights from studies in cultured endothelial cells,
the extent to which DHFR regulates intracellular BH4 levels and eNOS
uncoupling in vivo remains unknown. We previously demonstrated
that DHFR activity is critical in regulating BH4:BH2 ratio and hence
eNOS coupling in vitro, particularly at low biopterin levels. Accord-
ingly, we compared the effect of DHFR inhibition by methotrexate
(MTX) treatment on BH4 levels and eNOS coupling in vivo, using mice
with either BH4 deﬁciency (hph-1) or elevated BH4 levels due to
GTPCH overexpression (GCH-Tg) in comparison with wild-type mice.
We report that DHFR activity is required to maintain BH4 levels in
vivo and that DHFR protein activity is required to maintain efﬁcient
coupling of eNOS in the hph-1 mouse in which BH4 levels are
deﬁcient. BH4 augmentation, as in the endothelium of the GCH-Tg
mouse, protects against these deleterious effects of DHFR inhibition
by MTX.
Methods
Experimental animals
The hph-1 mouse, generated by ENU mutagenesis, was used as a
model of BH4 deﬁciency [13]. In these animals, tissue BH4 levels are
low because of constitutively reduced expression of GTPCH. GCH-Tg
mice, in which human GTPCH transgene overexpression is targeted to
the endothelium under control of the murine Tie-2 promoter, were
generated in a C57BL/6 background as described previously [14].
Sixteen- to 20-week-oldmice were housed in temperature-controlled
cages (20 to 22 °C) with a 12-h light–dark cycle and were given free
access to water and formulated diets.
Treatment of experimental animals with methotrexate
To avoid nonspeciﬁc effects of MTX treatment, three low doses of
MTX (2 mg/kg) were injected intraperitoneally (ip) into wild-type,
hph-1, or GCH-Tg mice. A gap of 48 h was left between each injection.
Control animals were administered phosphate-buffered saline (PBS),
again by ip injection at 48-h intervals. MTX was freshly dissolved in
sterile phosphate-buffered saline and used within 10 min. All studiesinvolving laboratory animals were conducted in accordance with the
UK Home Ofﬁce Animals (Scientiﬁc Procedures) Act 1986.
Western blotting
Tissue lysates were prepared by homogenization in RIPA lysis buffer
(20 mmol/L Tris–HCl, 150 mmol/L NaCl, 1 mmol/L Na2EDTA, 1 mmol/L
EGTA, 1% Triton, 0.1% SDS, 0.1 sodiumdeoxycholate, pH 7.4) including a
cocktail of protease inhibitors (Roche, West Sussex, UK) and subjected
to three freeze–thaw cycles in liquid nitrogen. Western blotting was
carried out using standard techniques and anti-eNOS (BD Transduction
Laboratories, UK), -DHFR, -GTPCH, and -GAPDH antibodies.
Quantitative real-time RT-PCR
Total RNA was extracted from snap-frozen tissue in 1 ml of Trizol
solution by homogenization. Total RNA was quantiﬁed with RiboGreen
RNA reagent (Invitrogen, UK). RT-PCR was completed with SuperScript
II (Invitrogen, USA) using 1 μg total RNA and the TaqMan gene expression
system.QuantitativePCRwasperformedwith50 ng/μl cDNAonan iCycler
IQ real-time detection system (Bio-Rad Laboratories, USA) using gene
expression assays (Applied Biosystems, USA). Gene expression levels of
mouseGCH1andmouseDHFRwerenormalized to thehousekeepinggene
GAPDH.
Measurement of dihydrofolate reductase activity by HPLC
To determine DHFR activity in cells and tissues, we adapted a highly
sensitive HPLC method [15]. Brieﬂy, cell lysates or tissue homogenates
were incubatedwith dihydrofolate (50 μmol/L) for 20 min at 37 °C, in
a 0.1 mol/L potassium phosphate assay buffer (pH 7.4) containing
200 μmol/L NADPH, 1 mmol/L dithiothreitol (DTT), 0.5 mmol/L KCl,
1 mmol/L EDTA, and 20 mmol/L sodium ascorbate. After 30 min at
37 °C, the reaction was terminated by the addition of 0.2 mol/L
trichloroacetic acid. A stabilization solution (200 mg of sodium
ascorbate and 30 mg of DTT in 1 ml of water) was then added and
samples were stored at−20 °C until analysis.
The accumulation of the reaction products, tetrahydrofolate (THF)
and methyltetrahydrofolate (MeTHF), was then quantiﬁed by HPLC
using ﬂuorescence detection (295 nm for excitation and 365 nm for
emission). Dihydrofolate (DHF) was detectable only at concentrations
over 1000 times more than those of both THF and MeTHF.
DHFR knockdown by RNA interference
DHFR “ON-TARGETplus SMARTpool” small interfering RNA
(siRNA) was purchased from Dharmacon Thermo Scientiﬁc. The
siRNAs were used as a pool of four speciﬁc siRNA duplexes with the
following sequences, as previously described [11]: DHFR duplex 1—
AGUUUGAAGUCUACGAGAA, DHFR duplex 2—AGAAAGCACAGUUGG-
GAUA, DHFR duplex 3—GCCUGUAGGUUGUCUAAUA, and DHFR duplex
4—GCAAGUAAAUGUGUUGUAA.
Murine sEnd.1 endothelial cells were grown in Dulbecco's
modiﬁed Eagle medium (Gibco Life Technologies, USA) supplemented
with glutamine (2 mmol/L), penicillin (100 U/ml), and streptomycin
(0.1 mg/ml). Cells were seeded into six-well plates, cultured for 24 h,
and then transfectedwithDHFR-speciﬁc siRNA (100 nmol/L)orGAPDH-
positive (100 nmol/L) or nonspeciﬁc pooled duplex negative control
siRNA (100 nmol/L). After 72 h gene silencing was detected by analysis
of DHFR protein by Western blotting using DHFR-speciﬁc antibodies.
Biopterin quantiﬁcation by HPLC with electrochemical detection
BH4, BH2, and biopterin (B) levels in tissue homogenates or intact
mouse aorta were determined by HPLC followed by electrochemical
and ﬂuorescence detection, as previously described [16]. Brieﬂy,
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intact aorta was resuspended in 300 μl of PBS (50 mmol/L; pH 7.4),
containing dithioerythritol (DTE; 1 mmol/L) and EDTA (100 μmol/L),
and either homogenized (for lung tissue) or subjected to three
freeze–thaw cycles (for aorta). After centrifugation (15 min at
13,000 rpm and 4 °C), samples were transferred to new, cooled
microtubes and precipitated with cold phosphoric acid (1 mol/L),
trichloroacetic acid (2 mol/L), and DTE (1 mmol/L). Samples were
vigorously mixed and then centrifuged for 15 min at 13,000 rpm and
4 °C. Samples were injected onto an isocratic HPLC system and
quantiﬁed using sequential electrochemical (Coulochem III; ESA Inc.,
MA, USA) and ﬂuorescence (Jasco, UK) detection. HPLC separation
was performed using a 250-mm, ACE C-18 column (Hichrom, UK)
andmobile phase comprising sodium acetate (50 mmol/L), citric acid
(5 mmol/L), EDTA (48 μmol/L), and DTE (160 μmol/L) (pH 5.2) (all
ultrapure electrochemical HPLC grade), at a ﬂow rate of 1.3 ml/min.
Background currents of +500 and −50 μA were used for the
detection of BH4 on electrochemical cells E1 and E2, respectively.
BH2 and biopterin were measured using a Jasco FP2020 ﬂuorescence
detector. Quantiﬁcation of BH4, BH2, and B was done by comparison
with authentic external standards and normalized to sample protein
content. Total biopterin levels are expressed as the sum of detectable
BH4, BH2, and B.
GTPCH activity assay
GTPCH activity was measured in tissue extracts by HPLC analysis
after iodine oxidation as described previously [17]. In brief, snap-
frozen tissue samples were homogenized and cell pellets were
freeze–thawed in lysis buffer (0.1 M Tris, 0.3 M potassium chloride,
2.5 mM EDTA, 100 μM phenylmethylsulfonyl ﬂuoride, pH 7.8). Lysates
were incubated for 1 h (37 °C) with 10 mM GTP in the absence of
light and then oxidized with potassium iodide/iodine (0.1 mol/L).
After deproteinationwith HCl (1 mol/L), the reactionwas stopped by
the addition of ascorbic acid (0.1 mol/L) and alkaline phosphatase
(16 U/ml). Neopterin content was quantiﬁed by isocratic HPLC and
ﬂuorescence detection (Jasco, UK). Quantitation of neopterin was
carried out by comparison with external standards and normalized for
sample protein content. The protein concentration of each sample was
measured using the BCA protein assay (Pierce, USA).
Analysis of NO synthesis by eNOS
Cellular NO synthesis by eNOS was assessed in lung homogenates
by measuring the conversion of L-[14C]arginine to citrulline with HPLC
detection, in the presence and absence of L-NMMA, as previously
described [18]. Samples were homogenized in Krebs–Hepes buffer in
the presence of the arginase inhibitor Nor-NOHA (5 μmol/L) and the
accumulation of [14C]citrulline was assessed after a 30-min incubation
with calcium ionophore (1 μmol/L).
Quantiﬁcation of superoxide production by HPLC
Measurement of 2-hydroxyethidium formation by HPLCwas used
to quantify superoxide production by methods adapted from those
previously described [19,20]. Quantiﬁcation of the “ethidium” peak
was used as an indicator of total reactive oxygen species production
[21]. Lung homogenates were prepared in Krebs–Hepes buffer in the
presence and absence of the NOS inhibitor L-NAME (100 μmol/L).
After 30 min incubation at 37 °C, dihydroethidium (50 μmol/L) was
added. After a further 20 min, cells were lysed in ice-cold methanol
(1:1 v/v). Hydrochloric acid (100 mmol/L) was added (1:1 v/v)
before loading into the autosampler for analysis. All samples were
stored in darkened tubes and protected from light at all times.
Separation of dihydroethidium, 2-hydroxyethidium, and ethidium
was performed using a gradient HPLC system (Jasco) with an ODS3reverse-phase column (250 mm, 4.5 mm; Hichrom, UK) and quan-
tiﬁed using a ﬂuorescence detector set at 510 nm (excitation) and
595 nm (emission). A linear gradient was applied frommobile phase
A (0.1% triﬂuoroacetate (TFA)) to mobile phase B (0.085% TFA in
acetonitrile) over 23 min (30% acetonitrile to 50% acetonitrile).Statistical analysis
Data are presented as means±SEM. Data were subjected to the
Kolmogorov–Smirnov test to determine distribution. Groups were
compared using theMann–Whitney U test for nonparametric data or
the Student t test for parametric data. When comparing multiple
groups, data were analyzed by analysis of variance with a Bonferroni
posttest. A value of Pb0.05 was considered statistically signiﬁcant.Results
Characterization of wild-type, hph-1, and GCH-Tg mice
We ﬁrst set out to characterize the respective mouse models of
BH4 deﬁciency (hph-1) and BH4 augmentation (GCH-Tg), by the
determination of the relative expression levels of eNOS, GTPCH, and
DHFR proteins in the presence and absence of MTX. Whereas eNOS
protein levels were equal, GTPCH protein was increased by over 20-
fold in GCH-Tg compared to wild-type mice, and GTPCH protein in
the hph-1 mouse was barely detectable. DHFR protein levels were
variable in wild-type, hph-1, and GCH-Tg mice, but no signiﬁcant
difference was observed (Figs. 2A and B). Moreover, wild-type, but
not hph-1 or GCH-Tg mice, exhibited a small but signiﬁcant increase
in DHFR mRNA levels in lung tissue after exposure to MTX compared
to control PBS-treated mice (Fig. 2C). These observations of variable
increases in both DHFR protein and mRNA levels after treatment of
wild-type, hph-1, and GCH-Tg mice with MTX have been previously
demonstrated. DHFR levels are increased in mouse lung and kidney
after treatmentwithMTX by subcutaneous infusion [22] and in Chinese
hamster ovary cells [23,24], human lymphoblasts [25], and astrocytes
[26] after exposure toMTX in culture. Importantly, potentially confound-
ing nonspeciﬁc effects of MTX were not demonstrated on the levels of
either eNOS or GTPCH protein.Effects of methotrexate on DHFR activity
We next sought to investigate the effects of systemic inhibition of
DHFR activity in lung tissue from wild-type, hph-1, and GCH-Tg
animals treated with either MTX or placebo. To demonstrate that our
in vivo ip MTX treatment was sufﬁcient to induce inhibition of DHFR
protein activity, we adapted a previously published HPLC-based
method [15]. After incubation of lung tissue homogenates with the
substrate dihydrofolate, the accumulation of tetrahydrofolate was
quantiﬁed as an indicator of DHFR activity. Importantly, THF and
MeTHF were easily separated by HPLC (Fig. 3A). Approximately
1000-fold more DHF than either THF or MeTHF was required to be
detectable by ﬂuorescence (data not shown). To test the dependence
of THF accumulation on DHFR activity, we exposed murine endothelial
cells to DHFR-speciﬁc siRNA. Subsequently, DHFR protein was dimin-
ished by over 95%, which resulted in a 90% reduction in measurable
THF and therefore DHFR activity (Fig. 3B). As it was important to
eliminate any confounding effects of our MTX-dosing regimen on
intracellular THF levels within lung tissue, THF concentration in lung
homogenates was quantiﬁed by HPLC. Endogenous basal levels of
THF were comparable in wild-type, hph-1, and GCH-Tg mouse lung
tissue and remained unaffected by MTX (Fig. 3C). In contrast, MTX
treatment of wild-type, hph-1, and GCH-Tg mice was sufﬁcient to
signiﬁcantly inhibit lung DHFR activity in all genotypes (Fig. 3D).
Fig. 2. Characterization of wild-type, hph-1, and GCH-Tg mice. 16- to 20-week-old mice were treated with three ip injections of either PBS (control) or MTX as detailed under
Methods. The animals were sacriﬁced and lung tissue was harvested for analysis by Western blotting using eNOS-, GTPCH-, and DHFR-speciﬁc antibodies. Representative blots are
shown; n=3. (A) eNOS protein levels were comparable in all three groups. GTPCH protein levels were diminished in hph-1 and elevated by 20-fold in GCH-Tg mouse lung
homogenates, compared to wild-type controls. MTX treatment did not alter the protein levels of either eNOS or GTPCH protein. (B) DHFR protein was elevated in wild-type, but not
hph-1 or GCH-Tg mouse lung tissue in response to MTX treatment, as measured by densitometric analysis of the DHFR band. (C) DHFR mRNA was increased by MTX in wild-type
(Pb0.05) but not hph-1 or GCH-Tg animals (n=3).
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Having demonstrated that MTX treatment of mice is sufﬁcient to
induce inhibition of DHFR activity without confounding effects on
basal THF levels, we reasoned that this would have important effects
on biopterin homeostasis and the redox state of intracellular BH4. WeFig. 3. DHFR protein activity is inhibited by MTX treatment. 16- to 20-week-old mice were
tissue was harvested and DHFR activity measured by HPLC. For cell culture siRNA experim
scrambled nonspeciﬁc siRNA as described. (A) Example chromatogram showing THF and
knocked down by over 90% in endothelial cells using DHFR-speciﬁc siRNAs. Cells were incub
measured by HPLC as an indicator of DHFR activity. DHFR siRNAs resulted in an 80% inhibition
wild-type, hph-1, or GCH-Tg mouse lung tissue (n=6!10). (D) DHFR activity was signiﬁcan
hph-1, and GCH-Tg mice (n=6–10, *Pb0.05).compared BH4 levels in the lung and aorta of wild-type, hph-1, and
GCH-Tg mice after ip treatment of mice with MTX or the placebo, PBS.
No signiﬁcant effect of MTX was observed in lung tissue from wild-
type mice. However, striking oxidation of BH4 to BH2 occurred in the
hph-1 mouse (Fig. 4): BH4 was signiﬁcantly decreased (2.0±0.5 vs
0.9±0.2, Pb0.05) and BH2 elevated (2.0±0.3 vs 3.0±0.7, Pb0.05),treated with three ip injections of either PBS or MTX as detailed under Methods. Lung
ents, sEnd.1 murine endothelial cells were transfected with DHFR-speciﬁc or control
MeTHF standards at a range of concentrations (0–100 nmol/L). (B) DHFR protein was
ated with DHF (50 μmol/L) and NADPH (200 μmol/L), and the accumulation of THF was
of DHFR activity (n=6, Pb0.01). (C) MTX treatment had no effect on basal THF levels in
tly decreased after MTX but not PBS (control) treatment in lungs taken from wild-type,
1643M.J. Crabtree et al. / Free Radical Biology & Medicine 50 (2011) 1639–1646resulting in a marked reduction in the BH4:BH2 ratio, a key
determinant of eNOS coupling (0.8±0.1 vs 0.3±0.1, Pb0.05). This
was probably due to the abrogation of the protective, reductive effect
of DHFR by the MTX treatment. Similarly, MTX treatment allowed for
increased oxidation of BH4 observed in the aorta of hph-1 mice.
Moreover, BH2 accumulation was also seen in the wild-type mouse
(0.4±0.1 vs 0.8±0.2, Pb0.05). Importantly, the reduction in BH4:
BH2 ratio induced by MTX in hph-1 lung homogenates was greater
than that observed in wild-type controls (2.6±1.1 vs 1.0±0.2,
Pb0.05), illustrating that the relative magnitude of the effect of DHFR
inhibition was greater at low vs high total biopterin levels. Indeed,
these MTX-induced changes did not occur in either the lung or the
aorta of GCH-Tg mice, in which total biopterin levels were
signiﬁcantly elevated. Because nonspeciﬁc effects of MTX treatment
on GTPCH activity could explain these changes in biopterin levels, we
eliminated this possibility by comparison of GTPCH enzymatic activity
measuredbyHPLC (Fig. 5). Theseﬁndings suggest thatDHFR is critical in0
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Fig. 4.MTX treatment leads to evidence of BH4 oxidation in lung and aorta. Wild-type,
hph-1, and GCH-Tg mice were treated with MTX or PBS as outlined under Methods.
Lung and aorta were harvested and processed for biopterin analysis by HPLC. (A) BH4
was signiﬁcantly oxidized (†Pb0.05), (B) BH2 was markedly elevated (†Pb0.05), and
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the BH4:BH2 ratio in hph-1 ($Pb0.05), but not wild-type or GCH-Tg lung tissue in
response to MTX treatment (n=6–10). (E, F, and G) Similarly, BH4 oxidation was
observed in the aorta of hph-1 mice. BH2 accumulation was also seen in the wild-type
mouse (F, †Pb0.05). An exacerbation of the BH4:BH2 ratio was revealed after ip MTX
treatment in hph-1 lung homogenates and aorta compared towild-type controls (D and
H, $Pb0.05). Total biopterin levels are expressed as the sum of detectable BH4, BH2, and
B (n=6–10, *Pb0.05, **Pb0.01).regulating BH4 redox state at low, but not high, levels of total biopterin,
at which de novo biosynthesis alone is probably sufﬁcient to maintain
saturating levels of BH4.DHFR activity is required for eNOS coupling under conditions of BH4
deﬁciency
Having observed marked changes in BH4, and in particular the
BH4:BH2 ratio, after MTX treatment, we reasoned that this would
have detrimental effects on eNOS coupling. The activity of eNOS (as
measured by quantifying the conversion of arginine to citrulline) was
modestly decreased in hph-1 mouse lung tissue and signiﬁcantly
elevated in GCH-Tg lung (Fig. 6). There was a further, signiﬁcant
decrease in eNOS activity in the MTX-treated hph-1mouse, compared
to both control-treated hph-1 and wild-type animals (0.08±0.03 vs
0.16±0.04 and 0.21±0.1, respectively, Pb0.05). In contrast, high
levels of BH4 in the GCH-Tg mouse protected against the MTX-
induced decrease in NO production, because we observed no difference
in lung eNOS activity in MTX-treated GCH-Tg mice. Simultaneously,
evidence of eNOS uncoupling was observed in the hph-1 lung after
exposure toMTX (Fig. 7). Elevated accumulation of 2-hydroxyethidium
(as an indicator of superoxide production) was detected in the lungs
of hph-1 compared to both wild-type and GCH-Tg mice (Pb0.05).
However, this superoxide production was inhibitable only with
the arginine analogue L-NAME in hph-1 mice post-MTX treatment
(0.51±0.06 vs 0.33±0.13, Pb0.05, Fig. 7A). Accordingly, marked
eNOS-derived superoxide production was evident only in the MTX-
treated hph-1 mouse (Fig. 7B). In further support of the protective role
of BH4 against MTX-induced oxidative stress, GTPCH overexpression
prevented any effect of MTX on either eNOS activity or superoxide
production.
Although the apparent switch from eNOS-independent to eNOS-
dependent superoxide production in hph-1 lung tissue in response to
MTX treatment is surprising, total levels of reactive oxygen species (as
quantiﬁed by the accumulation of ethidium in lung homogenates
after exposure to dihydroethidium) are 10-fold those of superoxide
(measured by the accumulation of 2-hydroxyethidium). The lack of
any inhibition of the formation of ethidium by L-NAME suggests that
the contribution of eNOS to total oxidant production is small
(Figs. 7C and D). The anti-inﬂammatory effects of MTX treatment
may attenuate superoxide production from other sources, and this
would mask any simultaneous increase in superoxide production
from eNOS becoming detectable in the hph-1 mouse.
Taken together, these data indicate that DHFR activity regulates
BH4 recycling and BH2 accumulation with simultaneous effects on
eNOS coupling. These data also reveal that DHFR is required to
maintain NOS coupling under conditions of low biopterin synthesis.WT hph-1 GCH-Tg
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Fig. 6. MTX-induced reduction in eNOS activity in hph-1 mice. Wild-type, hph-1, and
GCH-Tg mice were treated with MTX as outlined under Methods. Lung tissue
homogenates were incubated with Krebs–Hepes buffer containing calcium ionophore
(1 μmol/L) in the presence and absence of L-NAME (100 μM) for 30 min. L-[14C]
citrulline accumulation was then quantiﬁed by HPLC as an indicator of eNOS activity.
eNOS activity was decreased in the hph-1 mouse lung (although not signiﬁcantly) and
elevated in the GCH-Tg (*Pb0.05). eNOS activity in the MTX-treated hph-1 mouse lung
was signiﬁcantly decreased compared to both PBS-treated hph-1 andwild-type animals
(*Pb0.05). No effect of MTX was observed in the GCH-Tg mouse (n=6–10).
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In this study we tested a potential role for DHFR in regulating
biopterin redox state and eNOS coupling, using pharmacological
inhibition of DHFR by MTX in vivo. Advancing our previous studies in
cell culture [11], we compared BH4-deﬁcient (hph-1) and GTPCH-
overexpressing (GCH-Tg) mice with wild-type controls in the presence
and absence of MTX treatment. We reveal a key role for DHFR and the
recycling pathway of BH4 biosynthesis in the maintenance of
intracellular BH4 homeostasis in vivo and test the dependence of
eNOS coupling on DHFR activity under low biopterin conditions
observed in the hph-1 mouse. The major ﬁndings of this study are as
follows: ﬁrst, treatment of hph-1, wild-type, and GCH-Tg mice with
methotrexate leads to an approximately 60% reduction in DHFR activity.
Second, this diminished activity of the recycling pathway leads to BH4
oxidation as shown by a reduction in the BH4:BH2 ratio in mouse lung.
Third, a striking exacerbation of these effects occurs in both aorta and
lung of the hph-1 mouse model of BH4 deﬁciency compared to wild-
type controls. Fourth, these changes in biopterin redox status do not
occur when BH4 levels are high, as in the GCH-Tg animal. Finally, these0.0
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Fig. 7. DHFR regulates eNOS coupling in the hph-1 mouse lung. Wild-type, hph-1, and GCH-T
of 2-hydroxyethidium and ethidium in lung homogenates, after exposure to dihydroethidiu
reactive oxygen species production, respectively. (A) Elevated levels of 2-hydroxyethidium
(*Pb0.05). This superoxide production was attenuated by L-NAME (100 μmol/L) only in hp
evident only in the MTX-treated hph-1 mouse (*Pb0.05). (C) Levels of total reactive oxygen
(D) L-NAME treatment had no effect on the elevation of reactive oxygen species (P not signchanges in biopterin homeostasis result in eNOS uncoupling and the
productionof signiﬁcant levelsof eNOS-derived superoxide in thehph-1
mouse. Taken together our ﬁndings provide clear mechanistic evidence
to support a key role for the recycling pathway in the regulation of
cellular biopterin homeostasis in vivo and a regulatory role for DHFR on
eNOS coupling under conditions of BH4 deﬁciency.
Biosynthesis of BH4, initially characterized by its cofactor role
in reactions catalyzed by the aromatic amino acid hydroxylases,
proceeds via the de novo pathway involving the enzymes GTPCH,
6-pyruvoyltetrahydropterin synthase, and sepiapterin reductase (Fig. 1)
[27]. As the rate-limiting enzyme in BH4 synthesis, GTPCH regulation
takesplaceat the transcriptional andposttranslational levels,withactivity
andmRNAshown tobe inducedbymediators such as interferon-γ, tumor
necrosis factor-α, and lipopolysaccharide [28–30]. Indeed, steady-state
BH4 levels in cells and tissues have previously been shown to directly
correlate with GTPCH mRNA levels [31]. BH4, also a cofactor for NOS
enzymes, is required for efﬁcient oxidation of arginine and ultimately NO
production.WhenBH4 availability is limiting, eNOS generates superoxide
rather than NO, BH4 becomes oxidized to catalytically incompetent BH2,
and a feed-forward cascade of BH4 destruction proceeds.
A BH2 reductase activity of DHFR was ﬁrst observed in cell and
tissue extracts. In a Chinese hamster ovary cell mutant lacking
dihydrofolate reductase (DUKX-BII), endogenous formation of BH4
proceeds normally, but unlike the parent cells that express DHFR,
extracts do not convert sepiapterin or BH2 to BH4 [32]. These studies
implicate the biopterin recycling pathway in the regulation of steady-
state BH4 levels. Our data suggest that this BH2 reductase activity of
DHFR is crucial in determining cellular BH4 homeostasis, NO
bioavailability, and ultimately eNOS coupling in vivo, particularly in
BH4-deﬁcient states such as those found in the hph-1 lung.
Interestingly, some previous studies have shown that DHFR level or
activity is diminished in experimental models of cardiovascular
disease states, suggesting that insufﬁcient recycling of BH2 to BH4
by DHFR is at least in part responsible for the attenuated BH4 levels
and the accumulation of BH2, leading to eNOS uncoupling—the
marked accumulation of BH2, resulting from DHFR inhibition, would
compete with BH4 for eNOS binding, diminish NO production, and
elevate the synthesis of eNOS-derived superoxide. For example, DHFR
protein levels are signiﬁcantly decreased in streptozotocin-induced-0.2
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g mice were treated in vivo with MTX ip, as outlined under Methods. The accumulation
m (50 μmol/L), was quantiﬁed by HPLC and used as an indicator of superoxide and total
were detected in the lungs of hph-1 compared to both wild-type and GCH-Tg mice
h-1 mice post MTX treatment (†Pb0.05). (B) eNOS-derived superoxide production is
species were greater in hph-1 compared to both wild-type and GCH-Tg mice (*Pb0.05).
iﬁcant). Open bars, PBS; black bars, L-NAME treatment (n=6–10).
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function is exacerbated after treatment of the mice with the DHFR
inhibitor, MTX [33]. Furthermore, decreased DHFR activity in adult
cardiac myocytes underlies their limited capacity to synthesize BH4
after cytokine stimulation after treatment of rat cardiac allograft
recipients with sepiapterin [34]. Insufﬁcient DHFR activity might also
explain impaired vasorelaxation in atherosclerotic vessels from
hypercholesterolemic rabbits, despite exposure to sepiapterin, which
increases biopterin levels through BH2, requiring DHFR to increase BH4
[35].
Having previously demonstrated that BH4:BH2 ratio and eNOS
uncoupling relies more heavily on DHFR activity when total biopterin
levels are very low, we sought to compare two models exhibiting
differential levels of de novo biopterin synthesis, akin to our studies in
cells expressing tetracycline-regulatable GTPCH. The hph-1 mouse
model of BH4 deﬁciency and the GCH-Tg mouse enabled us to make
this comparison, and treatment of these mice with MTX (three ip
injections of 2 mg/kg) resulted in a dramatic attenuation of DHFR
activity.
Our data show that high levels of GTPCH activity, and therefore
BH4, are protective against the detrimental effects of MTX on eNOS
coupling. Moreover, as the levels of BH4 are increased in the GCH-Tg
mouse, the BH4:BH2 ratio remains unchanged. This would suggest
that as the de novo, synthetic pathway continues to produce more
BH4, BH2 also continues to accumulate. If no oxidation were to occur,
one would hypothesize that the ratio would in fact be increased. Even
when MTX treatment attenuates DHFR activity, no signiﬁcant change
in either lung or aortic BH4 homeostasis is observed in the GCH-Tg
mouse, indicating that the proportion of total biopterins from the
recycling pathway is very small. In contrast, in the hph-1 mouse, in
which tissue BH4 levels are decreased by up to 90%, attenuation of
DHFR activity leads to dramatic changes in biopterins and conse-
quently NO and superoxide production by eNOS. Hence, the relative
contribution made to total biopterins and BH4 redox status by the
recycling pathway, versus the synthetic pathway, is substantial. It is
well established that eNOS coupling is also determined by the relative
ratio of eNOS:BH4 [7,14]. Given that the total levels of BH4 in wild-
type aorta are somewhat lower than those in lung, it may be expected
that eNOS may be more susceptible to smaller changes in BH4:BH2 in
aorta. However, it is important to consider the possibility that the
tissues of the hph-1mouse are under relative oxidative stress and that
this elevated production of reactive oxygen species, rather than the
low concentrations of BH4, may make hph-1 tissues susceptible to
MTX-induced eNOS uncoupling.
These results in mice support our previous ﬁndings in cultured cells
in which concomitant exposure of endothelial cells to both GTPCH- and
DHFR-speciﬁc siRNA, inhibiting the synthetic and recycling pathways
together, signiﬁcantly elevated eNOS-derived superoxide compared
with either treatment alone. Similarly, although no evidence of eNOS
uncoupling was observed in hph-1 lung tissue alone, striking eNOS
uncouplingandBH4oxidationwerediscoveredwhenboth the synthetic
and the recycling pathwayswere diminished.We therefore hypothesize
that GTPCH is the principal enzyme determining overall production of
BH4, whereas DHFRmaintains the BH4 pool in a reduced state, limiting
the accumulation of oxidized biopterins. The absence of any effect of
MTX treatment in lung tissue from wild-type mice does not rule out a
role for DHFR in maintaining eNOS coupling when levels of BH4 are
saturating. An important limitation of the current study is that our
exposure of mice to MTX resulted in only a 60% inhibition of DHFR
activity—higher doses of MTX and the resulting greater inhibition of
DHFR may allow enhanced accumulation of BH2 and, potentially,
uncoupling of eNOS in wild-type mice. Our dose of 2 mg/kg was
carefully selected to inhibit DHFR activity without having confounding
effects on intracellular THF levels. We were therefore able to dose MTX
without folic acid, normally coadministered when targeting DHFR for
cancer and rheumatoid therapies. This was important because of thepotential nonspeciﬁc actions of folates on eNOS coupling and BH4
availability [36].
Pharmacological supplementation of BH4 improves endothelium-
dependent relaxation and augments NO-mediated effects on forearm
blood ﬂow in smokers and those with diabetes and elevated cholesterol
[37–39]. Inefﬁcient utilization of the administered BH4 remains
problematic [40,41]. Recent studies in cells and in vivo suggest that
DHFR is also required for biopterin transport. BH4 accumulation in
various tissues after supplementationwith BH4, BH2, or sepiapterin can
be inhibited byMTX; indeed after MTX treatment the increase in tissue
biopterin was almost exclusively BH2 [42]. It was concluded that the
elevation in BH4 by supplementation was mainly through a “salvage
pathway” that included BH2 as the key intermediate in the production
of BH4 through the action of dihydrofolate reductase. It is, therefore,
likely that DHFR expression is critical to cells that do not contain the
apparatus required for efﬁcient synthesis of BH4. BH2 may be
transported from cells such as endothelial cells, reduced back to BH4
by DHFR, andmade available for the synthesis of NO or catecholamines.
Our data suggest a potentially harmful effect of methotrexate
therapy on biopterin homeostasis and endothelial function. Given
the widespread clinical use of methotrexate, both as an anti-cancer
therapeutic and in inﬂammatory diseases such as rheumatoid
arthritis, further studies are merited to investigate and characterize
this impact more closely. BH4 supplementation during MTX therapy,
for example, may improve BH4/BH2 ratios, maintain vascular
function, and serve to diminish the risk of cardiovascular events in
these patients even further.
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